Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medigene Refills Its Early Pipeline By Buying Trianta Immunotherapies

This article was originally published in The Pink Sheet Daily

Executive Summary

For just under €10 million, Germany’s Medigene completes its restructuring with immunotherapy platform technologies that include dendritic cell vaccines, T-cell receptor based products and anti-T-cell monoclonal antibodies.

You may also be interested in...



MediGene’s ‘Airbag’ Equity Deal Provides EndoTAG-1 Partnering Flexibility

Option lets the firm sell up to 25M Euros in new stock to YA Global over three-year period.

Pipeline Watch: Phase III Starts For COVID-19 Vaccines

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Indivior Reorganizing And Re-Investing In US Commercial Functions

Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel